Evidence map›Paper›PMID 41586307›Full record

ArticleFrontiers in cellular and infection microbiology2025

Drug repurposing of Nifuratel against methicillin-resistant

Pengfei She, Bingqin Qin, Kening Lin, Di Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pengfei SheDepartment of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Bingqin QinDepartment of Laboratory Medicine, Chenzhou Third People's Hospital, Chenzhou, Hunan, China.
Kening LinDepartment of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Di ZhangDepartment of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The diminishing efficacy of conventional antibiotics against methicillin-resistant Methods: Results: Nifuratel exhibited potent bactericidal activity with MICs of 2-8 µg/mL and MBCs of 8-16 µg/mL, and a low propensity for resistance development. At sub-MIC concentrations, it significantly suppressed MRSA virulence phenotypes. Mechanistic studies revealed that Nifuratel disrupts the proton motive force by dissipating both the transmembrane potential and proton gradient, without causing direct membrane damage. Discussion: These results identify Nifuratel as a promising repurposed antimicrobial agent against MRSA. Its dual capability to exert direct bactericidal activity by disrupting PMF and attenuate key virulence factors, combined with a favorable resistance profile and biocompatibility

Indexed as

Anti-Bacterial AgentsDrug RepositioningMethicillin-Resistant Staphylococcus aureusProton-Motive ForceAbscessAnimalsBacterial LoadBiofilmsDisease Models, AnimalHemolysisHumansMiceMicrobial Sensitivity TestsStaphylococcal InfectionsVirulenceWound InfectionAnti-Bacterial Agentsdrug repurposingmethicillin-resistantmolecular dynamicsNifuratelproton motive forceStaphylococcus aureus

Identifiers

PMID41586307
PMCPMC12827513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.